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Research articleMultiple uncontrolled conditions and blood 
pressure medication intensification: an 
observational study
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Thomas K Houston5,6, Mark S Litaker2,7, Deborah A Levine8,9 and Monika M Safford4
Abstract
Background: Multiple uncontrolled medical conditions may act as competing demands for clinical decision making. 
We hypothesized that multiple uncontrolled cardiovascular risk factors would decrease blood pressure (BP) medication 
intensification among uncontrolled hypertensive patients.
Methods: We observed 946 encounters at two VA primary care clinics from May through August 2006. After each 
encounter, clinicians recorded BP medication intensification (BP medication was added or titrated). Demographic, 
clinical, and laboratory information were collected from the medical record. We examined BP medication 
intensification by presence and control of diabetes and/or hyperlipidemia. 'Uncontrolled' was defined as hemoglobin 
A1c ≥ for diabetes, BP ≥ 140/90 mmHg (≥ 130/80 mmHg if diabetes present) for hypertension, and low density 
lipoprotein cholesterol (LDL-c) ≥ 130 mg/dl (≥ 100 mg/dl if diabetes present) for hyperlipidemia. Hierarchical 
regression models accounted for patient clustering and adjusted medication intensification for age, systolic BP, and 
number of medications.
Results: Among 387 patients with uncontrolled hypertension, 51.4% had diabetes (25.3% were uncontrolled) and 
73.4% had hyperlipidemia (22.7% were uncontrolled). The BP medication intensification rate was 34.9% overall, but 
higher in individuals with uncontrolled diabetes and uncontrolled hyperlipidemia: 52.8% overall and 70.6% if systolic 
BP ≥ 10 mmHg above goal. Intensification rates were lowest if diabetes or hyperlipidemia were controlled, lower than if 
diabetes or hyperlipidemia were not present. Multivariable adjustment yielded similar results.
Conclusions: The presence of uncontrolled diabetes and hyperlipidemia was associated with more guideline-
concordant hypertension care, particularly if BP was far from goal. Efforts to understand and improve BP medication 
intensification in patients with controlled diabetes and/or hyperlipidemia are warranted.
Background
As the US population ages, increasing numbers of indi-
viduals have multiple medical conditions [1,2]. As a
result, primary care clinicians are increasingly seeing
patients with multiple conditions, such as diabetes and/or
hyperlipidemia, that contribute to increased risk of car-
diovascular disease (CVD). Although the two conditions
frequently occur in the same patient, little information is
available regarding how to prioritize disease management
and implement guideline-concordant care for complex
patients with multiple uncontrolled conditions [1-3]. In
practice, clinicians manage uncontrolled conditions
inconsistently at every clinical encounter [4-7], and rates
of simultaneous control of all co-existing conditions are
suboptimal [8].
The phenomenon of patients presenting for care with
uncontrolled conditions or risk factors and the clinician
not adjusting the medication regimen has been called
'clinical inertia' [9,10]. In primary care practice, there are
situations in which clinicians may choose not to follow
disease-specific guidelines or adhere to quality measures
based on clinically appropriate reasons. While reports of
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clinical inertia are accumulating, the reasons why it
occurs remain limited [11]. In addition, it is unknown
whether the presence of multiple uncontrolled conditions
contributes to clinical inertia.
To examine the role of multiple uncontrolled condi-
tions in clinical inertia, we studied the association of
blood pressure (BP) intensification and the presence and
control of two other CVD risk factors, diabetes and
hyperlipidemia, in patients with uncontrolled hyperten-
sion. We hypothesized that additional uncontrolled CVD
risk factors would act as competing demands, decreasing
the likelihood that clinicians would adjust BP medica-
tions when the patient's BP was above goal.
Methods
Setting and design
This study was conducted at two VA Medical Center pri-
mary care clinics in 2006. Of the 15 clinicians practicing
at the clinics, 13 chose to participate. We observed all
consecutive patient visits made to each clinician over the
observation period (two to nine weeks during May to
August 2006). Patient visits occurred on six to sixteen
half-day sessions of clinic and included 37 to 151 patient
visits, depending on the clinician.
Data sources
At each visit, research assistants recorded the patient's BP
as assessed by the nursing assistant or nurse, and the
value and date of the most recent hemoglobin A1c and
low density lipoprotein cholesterol (LDL-c) levels as
recorded in the medical record. A data collection tool
including this information was provided to the clinician
prior to seeing each patient. At the conclusion of the visit,
the clinicians recorded whether BP medications were
intensified. The BP, diabetes, and lipid medications at the
time of the visit were also recorded. The Birmingham VA
Medical Center's Institutional Review Board approved
the study protocol.
Study sample
We observed 946 consecutive patients and include in this
analysis the 387 patients who presented with uncon-
trolled BP. Patients who were seen more than once only
had their first visit analyzed. Uncontrolled BP was
defined as ≥ 140/90 mmHg, or ≥ 130/80 if the patient had
diabetes. Diabetes was defined according to Miller's defi-
nition: more than one ICD-9-CM code for diabetes
(250.xx) within two years prior to the observed visit, or a
prescription for any diabetes medication in the current
year [12]. Hyperlipidemia was defined as being on a lipid-
lowering medication within two years prior to the
observed visit, or an LDL-c ≥ 130 mg/dL at the visit, or ≥
100 mg/dL if the patient had diabetes.
Dependent variable: BP medications intensified
We defined BP medication as intensified if the clinician
indicated, on the data collection form, addition of a new
medication or increase in the dose of an existing medica-
tion. Clinicians indicated whether they intensified medi-
cations in all but 17 patients with uncontrolled high BP.
The 17 patients without indication of intensification were
classified as not intensified.
Main exposure: uncontrolled CVD risk factors
The main exposures of interest were uncontrolled diabe-
tes and uncontrolled hyperlipidemia. Uncontrolled dia-
betes was defined as most recent recorded A1c ≥ 7%.
Uncontrolled hyperlipidemia was defined as most recent
recorded LDL-c ≥ 130 mg/dL, or ≥ 100 mg/dL if the
patient had diabetes.
Because patients were consecutive primary care
patients, not all had diabetes or hyperlipidemia. There-
fore, for each patient we indicated which of the following
four mutually exclusive clinical scenarios was present:
uncontrolled hypertension and no diagnosed diabetes or
hyperlipidemia; controlled diabetes and/or hyperlipi-
demia; either uncontrolled diabetes or uncontrolled
hyperlipidemia; or both uncontrolled diabetes and
uncontrolled hyperlipidemia. Because our primary inter-
est was the effect of multiple uncontrolled conditions,
patients with known diabetes or hyperlipidemia but no
A1c or LDL-C in the record were categorized as having
the respective controlled condition. While other clinical
scenarios are possible, they occurred too rarely in our
sample for separate categorization.
Other independent variables: patient characteristics
Additional variables included age, gender, systolic and
diastolic BP values, and the total number of BP, diabetes,
and lipid medications prescribed in the 90 days prior to
the observed visit. Because so many patients who met the
uncontrolled BP criterion were very near the threshold,
we also constructed a variable reflecting mmHg of sys-
tolic BP above goal.
Analysis
Patient age, gender, total number of medications for
hypertension, diabetes, hyperlipidemia, BP level, and
mmHg above goal were examined across the four clinical
scenarios using Chi-square tests, analysis of variance, and
Kruskal-Wallis tests where appropriate. In addition, we
examined the proportions of patients whose BP medica-
tions were intensified for each patient characteristic, for
each risk factor separately, and for combinations of ele-
vated risk factors. Hierarchical logistic regression models
were constructed to identify independent associations
with BP medication intensification, adjusting for cluster-
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ing of patients within clinician and for patient factors.
The main exposure of interest was a categorical variable
representing the four clinical scenarios defined above.
The referent category was the scenario where the patient
had uncontrolled BP and controlled diabetes and/or
hyperlipidemia. All variables were retained in the multi-
variable model except patient gender, due to small num-
bers of women. We estimated adjusted odds ratios (OR)
and predicted probabilities, each with 95% confidence
intervals (CI), from these models. The predicted proba-
bilities of BP medication intensification for each of the
four clinical scenarios were calculated from these models
using the sample mean age, systolic BP, and sample
median number of total medications for hypertension,
diabetes, and hyperlipidemia.
Preliminary analyses indicated that intensification rates
were strongly associated with systolic BP level, with lower
rates for those with lower systolic BP. To examine the
robustness of the effect of multiple uncontrolled condi-
tions at even low elevations of systolic BP, we stratified
the sample on the median mmHg above the goal, which
was 10 mmHg. Therefore, the near-goal sample included
individuals with systolic BP of 130 to 139 mmHg if they
had diabetes, and 140 to 149 mmHg if they did not. We
also examined the effect of restricting the analysis to only
patients known to have hyperlipidemia and/or diabetes,
again stratifying on the median mmHg above goal (within
10 mmHg). Finally, we conducted a sensitivity analysis
that excluded patients without A1c or LDL-c assessed
from the analysis, rather than grouping them as con-
trolled.
Results
The 387 patients had mean age of 63 ± 13 years (range: 25
to 90), 3.6% were female, 51.4% had diabetes and 77.3%
had hyperlipidemia. The mean systolic BP was 146 ± 15
mmHg (range: 113 to 208), and 52.5% had systolic BP
level within 10 mmHg of their goal. The median number
of medications prescribed for hypertension, diabetes, and
hyperlipidemia at the time of the visit was 2 (range: 0 to
9). The proportion presenting with uncontrolled diabetes
or uncontrolled lipids was similar (25.3% versus 22.7%,
respectively). As expected, patient characteristics differed
across the four clinical scenario groups (Table 1). Patients
with neither diabetes nor hyperlipidemia were younger
and had lower systolic BP, and patients with uncontrolled
conditions were on more medications.
Overall, 34.9% (135/387) of patients had their BP medi-
cations intensified at the visit. In bivariate analysis (Table
2), age and gender had non-significant associations with
intensification. Both the absolute level of systolic BP and
the number of mmHg above goal were strongly and lin-
early associated with intensification, which were the only
significant bivariate associations with BP medication
intensification observed. Intensification rates trended
downward (non-significantly) with increasing numbers of
medications currently prescribed. When we restricted
the number of medications to include antihypertensives
only, we found this effect was primarily attributable to the
antihypertensive medications (data not shown). Patients
with controlled diabetes were intensified at a lower rate
(29.7%) than those with uncontrolled diabetes (36.7%) or
those who did not have diabetes (36.7%). Intensification
rates were similar for patients with uncontrolled (32.0%)
and controlled hyperlipidemia (33.2%), both at a lower
rate than patients without hyperlipidemia (42.1%). We
also found similar intensification rates for patients with
diabetes and hyperlipidemia separately (data not shown).
There was no difference in BP medication intensification
for patients with uncontrolled diabetes versus uncon-
trolled hyperlipidemia.
We observed a U-shaped relationship between the clin-
ical scenarios and intensification in bivariate analyses,
although the odds ratios were not statistically significant
(Table 2). That is, the lowest intensification rates were
among those with controlled diabetes or hyperlipidemia,
compared with those without either condition or with
uncontrolled diabetes or hyperlipidemia. BP medication
intensification rates increased as the number of total
uncontrolled conditions rose; however, patients without
either condition were intensified at a higher rate than
those patients with either controlled diabetes or hyperlip-
idemia. These associations strengthened when adjusted
for: age; systolic BP level; number of hypertension, diabe-
tes, and hyperlipidemia medications; and clustering
(Table 3). The U-shaped relationship was maintained for
the group with systolic BP elevation < 10 mmHg and ≥ 10
mm Hg, although it was statistically significant only in
the latter group.
Those with uncontrolled BP and either controlled dia-
betes or hyperlipidemia (but not both) had the lowest
rates of intensification, and those with all three uncon-
trolled conditions had the highest. This pattern was only
statistically significant among the group with the highest
BP. Intensification rates and the probability of intensify-
ing were markedly higher for the group further from BP
goal compared to those with minimally uncontrolled BP
(Table 3; Figure 1). Restricting the analysis to patients
with diabetes and hyperlipidemia revealed similar
increasing odds of BP medication intensification as the
number of uncontrolled conditions rose, although the
odds were only significant in the group with all three
uncontrolled conditions and systolic BP at least 10 mm
Hg above goal (odds ratio 4.55, 95% confidence interval
1.43 to 14.44, p = 0.01). Results were similar in the sensi-
tivity analysis in which we excluded patients with missing
A1c and LDL-c values, rather than grouping them as con-
trolled (data not shown).
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Table 1: Characteristics of 387 patients presenting with uncontrolled blood pressure, overall and by clinical scenario
Clinical Scenario: Uncontrolled BP AND
Patient Factors All No diagnosed 
diabetes or HLD†
(N = 76)
Controlled diabetes 
and/or HLD
(N = 157)
Either uncontrolled 
diabetes or HLD
(N = 122)
Both uncontrolled 
diabetes and HLD
(N = 32)
P
N % N % N % N % N %
Age (years) < 0.001
< 55 92 23.8% 32 42.1% 22 14.0% 31 25.4% 7 21.9%
55 to 64 136 35.1% 15 19.7% 56 35.7% 50 41.0% 15 46.9%
65+ 159 41.1% 29 38.2% 79 50.3% 41 33.6% 10 31.2%
Gender 0.80
Male 373 96.4% 74 97.4% 152 96.8% 117 95.9% 30 93.7%
Female 14 3.6% 2 2.6% 5 3.2% 5 4.1% 2 6.3%
Systolic BP (mmHg) < 0.001
< 140 122 31.5% 12 15.8% 39 24.8% 55 45.1% 16 50.0%
140 to 159 196 50.6% 52 68.4% 89 56.7% 44 36.1% 11 34.4%
160+ 69 17.8% 12 15.8% 29 18.5% 23 18.8% 5 15.6%
Minimally (0 to 9 mmHg) above goal 0.13
Yes 203 52.5% 49 64.5% 78 49.7% 61 50.0% 15 46.9%
No 184 47.5% 27 35.5% 79 50.3% 61 50.0% 17 53.1%
Number of medications* < 0.01
0 122 31.5% 44 36.1% 51 41.8% 23 18.8% 4 3.3%
1 to 2 114 29.5% 22 19.3% 48 42.1% 37 32.5% 7 6.1%
3 to 4 97 25.1% 9 9.3% 35 36.1% 39 40.2% 14 14.4%
5+ 54 13.9% 1 1.8% 23 42.6% 23 42.6% 7 13.0%
Diabetes < 0.001
Uncontrolled 98 25.3% 0 0.0% 0 0.0% 66 54.1% 32 100.0%
Controlled** 101 26.1% 0 0.0% 69 43.9% 32 26.2% 0 0.0%
Not present 188 48.6% 76 100.0% 88 56.1% 24 19.7% 0 0.0%
HLD† < 0.001
Uncontrolled 88 22.7% 0 0.0% 0 0.0% 56 45.9% 32 100.0%
Controlled** 196 50.7% 0 0.0% 143 91.1% 53 43.4% 0 0.0%
Not present 103 26.6% 76 100.0% 14 8.9% 13 10.7% 0 0.0%
*Medications for hypertension, diabetes, and/or hyperlipidemia prescribed in the 90 days prior to the index visit; **Includes missing laboratory data: 23 A1c data, 41 lipids; †HLD = 
Hyperlipidemia
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Table 2: Bivariate associations with blood pressure medication intensification among 387 patients presenting with 
uncontrolled blood pressure
BP medication intensification rates Odds ratio 95% Confidence Interval
Patient Factors # intensified/total # % lower limit upper limit P
Age (years)
< 55 28/92 30.4 0.61 0.35 1.06 0.29
55 to 64 57/136 41.9 Referent
≥ 65 50/159 31.5 0.64 0.39 1.03 0.36
Sex
Male 133/373 35.7 Referent
Female 2/14 14.3 0.3 0.07 1.36 0.12
Systolic BP (mmHg) (mean)
< 140 21/122 17.2 Referent
140 to 159 72/196 36.7 2.79 1.61 4.85 0.93
≥ 160 42/69 60.9 7.48 3.81 14.68 < 0.001
Systolic BP < 10 mmHg above 
goal
Yes 39/203 19.2 Referent
No 96/184 52.2 4.59 2.92 7.22 < 0.01
Number of medications* 
0 39/122 31.5 0.68 0.35 1.33 0.35
1 to 2 40/114 29.5 Referent
3 to 4 34/97 25.1 0.79 0.40 1.53 0.89
5+ 22/54 13.9 0.79 0.40 1.56 0.89
Diabetes
Present-Uncontrolled 36/98 36.7 1.37 0.76 2.49 0.52
Present-Controlled** 30/101 29.7 Referent
Not present 69/188 36.7 1.37 0.82 2.30 0.46
Hyperlipidemia
Present-Uncontrolled 33/103 32.0 1.46 0.87 2.45 0.11
Present-Controlled** 65/196 33.2 Referent
Not present 37/88 42.1 0.95 0.57 1.58 0.33
Clinical scenario: 
Uncontrolled BP AND
No diagnosed diabetes or 
HLD†
30/76 39.5 1.53 0.86 2.71 0.72
Controlled diabetes and/or 
HLD
47/157 29.9 Referent
Either uncontrolled diabetes 
or HLD
43/122 35.3 1.27 0.77 2.11 0.56
Both uncontrolled diabetes 
and HLD
15/32 46.9 2.07 0.95 4.48 0.18
*Medications for hypertension, diabetes, and/or hyperlipidemia prescribed in the 90 days prior to the index visit; **Includes missing 
laboratory data: 23 hemoglobin A1c levels and 41 lipid levels; †HLD = Hyperlipidemia
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Discussion
In this study, patients with multiple uncontrolled CVD
risk factors were more likely to have BP medication inten-
sified, contrary to our expectations. Our hypothesis that
multiple uncontrolled CVD risk factors, specifically dia-
betes and hyperlipidemia, would act as competing
demands and thereby distract clinicians from treating ele-
vated BP was not supported. Higher BP medication
intensification rates in patients with multiple uncon-
trolled conditions suggest that clinicians may be appro-
priately identifying and managing high-risk patients with
uncontrolled hypertension, those patients with higher
CVD risk who are more likely to benefit from BP control.
Our results are concordant with other studies indicat-
ing better quality of care for medically complex patients
[13,14]. Heisler et al. also reported higher medication
intensification rates among patients with higher BPs [15].
We found that other uncontrolled CVD risk factors had a
similar effect and did not in fact 'compete' for the clini-
cian's attention to BP management. Because many of
these patients had additional medical conditions besides
diabetes and/or hyperlipidemia, further investigation is
needed to assess the effect of conditions unrelated to
CVD risk on decision-making and disease management
[16]. Particularly, it is not clear how painful arthritis, for
example, influences CVD risk factor management.
These findings reinforce our and others' work suggest-
ing that inaction by clinicians is not necessarily clinical
inertia [11,17]. Inaction may include both appropriate
and inappropriate clinical care. Appropriate inaction,
such as not intensifying medications in the setting of
non-adherence, reflects the challenge of applying guide-
lines to the care of individual patients balanced with
meeting population-based quality indicators. We noted a
considerable amount of appropriate action in the situa-
tion of medication intensification for the highest risk
patients (BP at least 10 mmHg above goal and uncon-
trolled diabetes and hypertension).
On the other hand, intensification rates observed when
the BP was closer to goal were quite low and may repre-
sent appropriate inaction. In these modest ranges of ele-
vation, clinicians may be more cautious, possibly
weighing the modest benefits against the potential harms
of a more intense regimen. The difference in manage-
ment of patients close to BP goals and those with higher
BP highlights the intricacy of providing guideline-concor-
dant yet patient-centered care in primary care. Addition-
ally, BP measurement is known to be imprecise, and low
Table 3: Adjusted odds ratios of blood pressure medication intensification for patients with uncontrolled blood pressure
95% Confidence Interval
Clinical scenario: Uncontrolled BP AND Odds ratio* lower limit upper limit P
ALL (N = 387)
No diagnosed diabetes or hyperlipidemia 1.86 1.04 3.33 0.04
Controlled diabetes and/or hyperlipidemia Referent
Either uncontrolled diabetes or hyperlipidemia 1.54 0.97 2.43 0.07
Both uncontrolled diabetes and hyperlipidemia 2.91 1.48 5.72 < 0.01
Systolic BP < 10 mmHg above goal (N = 203)
No diagnosed diabetes or hyperlipidemia 1.17 0.41 3.34 0.77
Controlled diabetes and/or hyperlipidemia Referent
Either uncontrolled diabetes or hyperlipidemia 0.92 0.43 1.94 0.82
Both uncontrolled diabetes and hyperlipidemia 1.69 0.26 11.07 0.58
Systolic BP ≥ 10 mm Hg above goal (N = 184)
No diagnosed diabetes or hyperlipidemia 2.58 1.17 5.67 0.02
Controlled diabetes and/or hyperlipidemia Referent
Either uncontrolled diabetes or hyperlipidemia 1.93 0.95 3.93 0.07
Both uncontrolled diabetes and hyperlipidemia 4.51 1.46 13.94 0.01
*Adjusted for age, systolic blood pressure, number of medications and clustering of patients by provider
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elevations may require close monitoring to assess the sta-
bility of the level. Further, the risks of polypharmacy are
real and an important potentially appropriate reason to
forego intensification of the BP regimen. In addition, a
single BP level does not reflect past efforts, which may
have resulted in considerable BP lowering and cardiovas-
cular risk reduction. Unfortunately, dichotomous quality
indicators, including the one assessing BP control, do not
acknowledge the subtleties involved in 'real world' clinical
decision making, nor do they account for appropriate
inaction. In fact, tying rewards to a simplistic quality indi-
cator that overlooks potentially clinically appropriate
inaction may result in unintended consequences, creating
incentives for polypharmacy and raising costs.
We observed that clinicians were possibly inappropri-
ately overestimating the benefit derived from controlled
diabetes and/or hyperlipidemia. BP medication intensifi-
cation rates were consistently the lowest for individuals
with either controlled diabetes or hyperlipidemia even
with systolic BP > 10 mm Hg above goal. These rates were
lower than for individuals with only uncontrolled hyper-
tension, and including the number of hypertension, dia-
betes, and hyperlipidemia medications in the model did
not change this effect. Controlled diabetes and/or hyper-
lipidemia lowers but does not eliminate the risk of CVD,
so efforts to improve BP control remain important in
reducing CVD risk [18]. In light of recent data from the
ACCORD study, control of systolic BP to 120 mm Hg
failed to demonstrate a decrease in major cardiovascular
events in patients with diabetes compared to less strin-
gent BP (systolic BP < 140 mm Hg) [19,20]. Regardless,
lack of treatment intensification when BP is notably
above goal among patients with known but controlled
diabetes and/or hyperlipidemia could be the target of
quality improvement activities, and may represent true
clinical inertia.
Our study of clinicians who practice in a healthcare sys-
tem with strong quality improvement initiatives and
incentives to control BP allowed us to observe whether
clinicians implement guidelines differently based on indi-
vidual patient factors, including the benefits and risks of
medication intensification. These individual patient fac-
tors and complex clinical decisions may not be apparent
by measuring quality indicators using administrative data
and may only be documented with observational data.
Our study has several limitations. Although the sample
of 13 clinicians at one VA facility caring for mostly male
patients raises issues of generalizability, our results con-
firm past reports of better quality of care with more med-
ically complex patients. With only 13 participating
clinicians, we were not able to explore clinician charac-
teristics that could be contributing to variations in care,
and this may warrant further investigation with a larger
study. Additionally, we may have seen higher rates of
Figure 1 Predicted probabilities of blood pressure medication intensification by clinical scenario among uncontrolled hypertensive pa-
tients. Error bars represent 95% confidence intervals.
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medication intensification than typical practice settings
because clinicians knew we were asking them to docu-
ment whether they changed medications. Our sample
was too small to confirm our preliminary findings sug-
gesting that BP medication intensification patterns were
similar for controlled versus uncontrolled hyperlipidemia
and for controlled versus uncontrolled diabetes. We were
also unable to conduct multivariate analyses of these
findings, which differ from past reports indicating that
hyperlipidemia is more often ignored compared to
uncontrolled diabetes or hypertension [21,22]. These
findings require confirmation in larger studies. Important
patient-level factors that could contribute to suboptimal
BP control and clinical inaction, such as cost or adher-
ence issues, were not available.
Summary
The presence of uncontrolled diabetes and hyperlipi-
demia increased the likelihood of BP medication intensi-
fication in patients with uncontrolled hypertension. This
effect was observed regardless of the level of BP elevation,
but the magnitude of the effect was greater if BP was fur-
ther from goal. These findings suggest that clinicians cor-
rectly identified and treated the highest risk hypertensive
patients likely to receive the greatest benefit with BP
medication intensification. Lower BP medication intensi-
fication rates seen in patients with modest BP elevations
and in patients with controlled diabetes and/or hyperlipi-
demia may represent appropriate clinical inaction and
inappropriate clinical inertia respectively, but further
investigation is needed. Our study reflects the complex
decision making process involved in providing medical
care that balances clinical guideline-concordance (based
on the benefit to groups or populations) and patient-cen-
teredness to patients with multiple uncontrolled condi-
tions. The implementation of quality indicators that
measure medication intensification, account for the clini-
cal risks and benefits of medication intensification, and
assess both appropriate clinical actions and inactions are
needed to maximize high quality, patient-centered care.
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